Accordingly, after the GBC2 patient received neoadjuvant chemotherapy of gemcitabine plus albumin-bound paclitaxel plus tislelizumab for 12 cycles, the size of tumor decreased by approximately 40% (Fig. 6H, I), indicating a partial response to the treatment. Here, ALB is linked to neoplasm.